- Home
- LOGI vs INCY Comparison
LOGI vs INCY Comparison
Compare LOGI & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOGI
- INCY
- Stock Information
- Founded
- LOGI 1981
- INCY 1991
- Country
- LOGI Switzerland
- INCY United States
- Employees
- LOGI N/A
- INCY N/A
- Industry
- LOGI Computer peripheral equipment
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- LOGI Technology
- INCY Health Care
- Exchange
- LOGI Nasdaq
- INCY Nasdaq
- Market Cap
- LOGI 12.4B
- INCY 13.4B
- IPO Year
- LOGI 1997
- INCY 1993
- Fundamental
- Price
- LOGI $104.00
- INCY $72.11
- Analyst Decision
- LOGI Hold
- INCY Buy
- Analyst Count
- LOGI 10
- INCY 20
- Target Price
- LOGI $97.13
- INCY $74.76
- AVG Volume (30 Days)
- LOGI 887.6K
- INCY 1.7M
- Earning Date
- LOGI 01-28-2025
- INCY 02-10-2025
- Dividend Yield
- LOGI 1.31%
- INCY N/A
- EPS Growth
- LOGI 39.12
- INCY N/A
- EPS
- LOGI 4.25
- INCY 0.15
- Revenue
- LOGI $4,556,032,000.00
- INCY $4,241,216,999.00
- Revenue This Year
- LOGI $6.18
- INCY $11.81
- Revenue Next Year
- LOGI $4.65
- INCY $10.71
- P/E Ratio
- LOGI $23.69
- INCY $427.87
- Revenue Growth
- LOGI 7.28
- INCY 14.76
- 52 Week Low
- LOGI $74.72
- INCY $50.35
- 52 Week High
- LOGI $105.65
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- LOGI 69.57
- INCY 51.77
- Support Level
- LOGI $102.88
- INCY $69.75
- Resistance Level
- LOGI $105.65
- INCY $72.69
- Average True Range (ATR)
- LOGI 1.36
- INCY 2.48
- MACD
- LOGI 0.04
- INCY -0.08
- Stochastic Oscillator
- LOGI 83.81
- INCY 57.46
About LOGI Logitech International S.A.
Logitech was founded in 1981 and is headquartered in Lausanne, Switzerland. The company specializes in designing and manufacturing computer peripherals such as mice, keyboards, webcams, conference room cameras, headsets, and music-related products such as wireless speakers.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.